Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuroendocrine differentiation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    63 result(s) found for: Neuroendocrine differentiation. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2010-023827-34 Sponsor Protocol Number: 1585/10 Start Date*: 2011-05-02
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS
    Medical condition: neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022273-34 Sponsor Protocol Number: CRAD001KDE37 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung c...
    Medical condition: large-cell neuroendocrine carcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004373-40 Sponsor Protocol Number: AveNEC Start Date*: 2017-08-21
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) pr...
    Medical condition: advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002605-65 Sponsor Protocol Number: DOTA2013/DOTATER Start Date*: 2013-11-26
    Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS
    Full Title: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors.
    Medical condition: Patients with tumors expressing somatostatin receptors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004259-35 Sponsor Protocol Number: Ebas0001 Start Date*: 2020-04-28
    Sponsor Name:Rigshospitalet
    Full Title: Ebastine in combination with docetaxel as a treatment for castration-resistant metastatic prostate cancer
    Medical condition: Male patients with metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003820-36 Sponsor Protocol Number: BAY1841788/17712 Start Date*: 2014-07-25
    Sponsor Name:Bayer AG
    Full Title: A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) HU (Completed) FI (Completed) LV (Completed) CZ (Completed) AT (Completed) GB (Completed) SK (Completed) DE (Completed) PT (Completed) IT (Completed) BE (Completed) BG (Completed) FR (Completed) PL (Completed) RO (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002725-74 Sponsor Protocol Number: COU-AA-004 Start Date*: 2007-07-16
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
    Medical condition: HRPC (Hormone refractory prostate cancer) refractory to androgen deprivation and Docetaxel based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005431-86 Sponsor Protocol Number: FuTuRe Start Date*: 2014-02-10
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
    Medical condition: Castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002993-11 Sponsor Protocol Number: 2016-02 Start Date*: 2016-10-26
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: A single arm phase 2 multicenter study determining the response to Cabazitaxel in metastatic prostate cancer (mCRPC) patients with AR-V7 positive circulating tumor cells (CTCs)
    Medical condition: metastatic castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001574-28 Sponsor Protocol Number: AT13387-04 Start Date*: 2012-10-09
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Phase 2 Study of Hsp90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
    Medical condition: Castration-Resistant Prostate Cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012453-38 Sponsor Protocol Number: Start Date*: 2009-09-14
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: A two-stage multicenter phase II trial of concurrent panitumumab immunotherapy, cisplatin chemotherapy and pelvic radiotherapy for primary cancer of the uterine cervix stage Ib-IIIb
    Medical condition: primary cancer of the uterine cervix stage Ib-IIIb
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002940-26 Sponsor Protocol Number: 212082PCR3011 Start Date*: 2013-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me...
    Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003865-32 Sponsor Protocol Number: TOK-200-11 Start Date*: 2014-02-12
    Sponsor Name:Tokai Pharmaceuticals, Inc.
    Full Title: A Pharmacokinetic and Pharmacodynamic Translational Investigation of Galeterone in Patients with Metastatic Castration Resistant Prostate Cancer
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10066489 Progression of prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002587-28 Sponsor Protocol Number: BGB-290-202 Start Date*: 2019-08-30
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD)
    Medical condition: Patients with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003549-72 Sponsor Protocol Number: SMR-3165 Start Date*: 2017-12-22
    Sponsor Name:Oncology Venture Aps
    Full Title: Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP™) indicating a high likelihood ...
    Medical condition: AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000580-93 Sponsor Protocol Number: SINTART2 Start Date*: 2013-05-04
    Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori
    Full Title: Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperab...
    Medical condition: Poor prognosis inoperable sinonasal tumors.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060768 Nasal neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000075-33 Sponsor Protocol Number: SINTART1 Start Date*: 2013-05-04
    Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori
    Full Title: Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in...
    Medical condition: Poor prognosis sinonasal tumors in operable patients.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060768 Nasal neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005837-13 Sponsor Protocol Number: COU-AA-301 Start Date*: 2008-06-10
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Doceta...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Docetaxel-Based Chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed) GB (Completed) FR (Completed) DE (Completed) BE (Completed) HU (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004429-17 Sponsor Protocol Number: CO39303 Start Date*: 2018-09-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/...
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed) PT (Completed) DE (Completed) DK (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) BE (Completed) ES (Ongoing) GR (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 13:42:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA